New therapeutic approaches for non-muscle invasive bladder cancer (NMIBC): intravesical use of oncotherad biological response modifier and its association with platelet-rich plasma (PRP)

Abstract

This study characterized the effects of the immunotherapy using the nanostructured complex OncoTherad, either associated or not to Platelet-Rich Plasm (PRP) on the non-muscle invasive bladder cancer (NMIBC) chemically induced in mice. The treatment with OncoTherad inhibited the cancer's progression and promoted tumoral regression in 85.7% and the OncoTherad associated with PRP in 71.4% of the animals. Thus, the immunotherapy using OncoTherad associated to PRP raises as a new therapeutic strategy for NMIBC, which allows the treatment's personalization and the reduction of the immunogenicity to patients who either show recurrence, are resistant to the therapy using Bacillus Calmette-Guérin (BCG) or are ineligible to the radical cystectomy.The immune system modulation and the relation of OncoTherad with the activated platelets demand continuity of studies to detail the mechanisms of this association.